Tiwari R, Manzar N, Bhatia V, Yadav A, Nengroo M, Datta D, et al. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. Nat Commun. 2020;11:384 pubmed publisher

Wu Z, Wang K, Yang Z, Pascal L, Nelson J, Takubo K, et al. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant ARF876L nuclear import and function. Prostate. 2020;80:319-328 pubmed publisher

Wang R, Lewis M, Lyu J, Zhau H, Pandol S, Chung L. Cancer-stromal cell fusion as revealed by fluorescence protein tracking. Prostate. 2020;80:274-283 pubmed publisher

Jiang L, Ivich F, Tahsin S, Tran M, Frank S, Miranti C, et al. Human stroma and epithelium co-culture in a microfluidic model of a human prostate gland. Biomicrofluidics. 2019;13:064116 pubmed publisher

Carrasco Pozo C, Tan K, Rodriguez T, Avery V. The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor. Int J Mol Sci. 2019;20: pubmed publisher

Nyquist M, Corella A, Mohamad O, Coleman I, Kaipainen A, Kuppers D, et al. Molecular determinants of response to high-dose androgen therapy in prostate cancer. JCI Insight. 2019;4: pubmed publisher

Grimaldi M, Boulahtouf A, Toporova L, Balaguer P. Functional profiling of bisphenols for nuclear receptors. Toxicology. 2019;420:39-45 pubmed publisher

Karpova Y, Wu C, Divan A, McDonnell M, Hewlett E, Makhov P, et al. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochem Pharmacol. 2019;: pubmed publisher

Peng C, Chen C, Chen C, Chen C, Shen K, Chen K, et al. Renal Damaging Effect Elicited by Bicalutamide Therapy Uncovered Multiple Action Mechanisms As Evidenced by the Cell Model. Sci Rep. 2019;9:3392 pubmed publisher

Han B, Min H, Jeon M, Kang B, Son J. A rapid non-target screening method for determining prohibited substances in human urine using liquid chromatography/high-resolution tandem mass spectrometry. Drug Test Anal. 2019;11:382-391 pubmed publisher

Browne J, Leir S, Eggener S, Harris A. Region-specific microRNA signatures in the human epididymis. Asian J Androl. 2018;20:539-544 pubmed publisher

Yang R, Browne J, Eggener S, Leir S, Harris A. A novel transcriptional network for the androgen receptor in human epididymis epithelial cells. Mol Hum Reprod. 2018;24:433-443 pubmed publisher

Axelrod H, Pienta K, Valkenburg K. Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells. Biol Proced Online. 2018;20:13 pubmed publisher

White M, Tsouko E, Lin C, Rajapakshe K, Spencer J, Wilkenfeld S, et al. GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. Endocr Relat Cancer. 2018;25:453-469 pubmed publisher

Horning A, Wang Y, Lin C, Louie A, Jadhav R, Hung C, et al. Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response. Cancer Res. 2018;78:853-864 pubmed publisher

McCarty D, Huang W, KANE M, Purushottamachar P, Gediya L, Njar V. Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model. Oncotarget. 2017;8:88501-88516 pubmed publisher

Chen R, Li Y, Buttyan R, Dong X. Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells. Oncotarget. 2017;8:84863-84876 pubmed publisher

Bluemn E, Coleman I, Lucas J, Coleman R, Hernández López S, Tharakan R, et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell. 2017;32:474-489.e6 pubmed publisher

Masoodi K, Eisermann K, Yang Z, Dar J, Pascal L, Nguyen M, et al. Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone. Endocrinology. 2017;158:3152-3161 pubmed publisher

Asim M, Tarish F, Zecchini H, Sanjiv K, Gelali E, Massie C, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8:374 pubmed publisher

Holmes B, Smeester L, Fry R, Weinberg H. Identification of endocrine active disinfection by-products (DBPs) that bind to the androgen receptor. Chemosphere. 2017;187:114-122 pubmed publisher

Jin L, Garcia J, Chan E, de la Cruz C, Segal E, Merchant M, et al. Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. Cancer Res. 2017;77:5564-5575 pubmed publisher

Magani F, Peacock S, Rice M, Martinez M, Greene A, Magani P, et al. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities. Mol Cancer Res. 2017;15:1469-1480 pubmed publisher

Hoy J, Kallifatidis G, Smith D, Lokeshwar B. Inhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival. Sci Rep. 2017;7:3058 pubmed publisher

Liu Y, Liu Y, Yuan B, Yin L, Peng Y, Yu X, et al. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription. Oncotarget. 2017;8:17027-17037 pubmed publisher

Zhang L, Zhao Z, Xu S, Tandon M, LaValle C, Deng F, et al. Androgen suppresses protein kinase D1 expression through fibroblast growth factor receptor substrate 2 in prostate cancer cells. Oncotarget. 2017;8:12800-12811 pubmed publisher

Askew E, Bai S, Parris A, Minges J, Wilson E. Androgen receptor regulation by histone methyltransferase Suppressor of variegation 3-9 homolog 2 and Melanoma antigen-A11. Mol Cell Endocrinol. 2017;443:42-51 pubmed publisher

Blessing A, Rajapakshe K, Reddy Bollu L, Shi Y, White M, Pham A, et al. Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. Autophagy. 2017;13:506-521 pubmed publisher

Okamoto M, Naka K, Ishiwata K, Shimizu I, Toyohara J. Synthesis and basic evaluation of 7?-(3-[18F]fluoropropyl)-testosterone and 7?-(3-[18F]fluoropropyl)-dihydrotestosterone. Ann Nucl Med. 2017;31:53-62 pubmed publisher

Colditz J, Rupf B, Maiwald C, Baniahmad A. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells. Mol Cell Biochem. 2016;421:139-47 pubmed publisher

Obinata D, Takayama K, Fujiwara K, Suzuki T, Tsutsumi S, Fukuda N, et al. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth. Oncogene. 2016;35:6350-6358 pubmed publisher

Fajardo A, MacKenzie D, Olguin S, Scariano J, Rabinowitz I, Thompson T. Antioxidants Abrogate Alpha-Tocopherylquinone-Mediated Down-Regulation of the Androgen Receptor in Androgen-Responsive Prostate Cancer Cells. PLoS ONE. 2016;11:e0151525 pubmed publisher

Davies E, Dong M, Gutekunst M, Närhi K, van Zoggel H, Blom S, et al. Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices. Sci Rep. 2015;5:17187 pubmed publisher

Malinen M, Toropainen S, Jääskeläinen T, Sahu B, Jänne O, Palvimo J. Androgen receptor- and PIAS1-regulated gene programs in molecular apocrine breast cancer cells. Mol Cell Endocrinol. 2015;414:91-8 pubmed publisher

Mehinto A, Jia A, Snyder S, Jayasinghe B, Denslow N, Crago J, et al. Interlaboratory comparison of in vitro bioassays for screening of endocrine active chemicals in recycled water. Water Res. 2015;83:303-9 pubmed publisher

Levina E, Ji H, Chen M, Baig M, Oliver D, Ohouo P, et al. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells. Oncotarget. 2015;6:13088-104 pubmed

Li H, Xie N, Gleave M, Dong X. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression. Oncotarget. 2015;6:20474-84 pubmed

Li H, Mohamed A, Sharad S, Umeda E, Song Y, Young D, et al. Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN. Oncotarget. 2015;6:15137-49 pubmed

Awasthi S, Ezelle H, Hassel B, Hamburger A. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells. Mol Cell Biochem. 2015;405:177-86 pubmed publisher

Santer F, Erb H, Oh S, Handle F, Feiersinger G, Luef B, et al. Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy. Oncotarget. 2015;6:6105-22 pubmed

Wu M, Kim S, Datta I, Levin A, Dyson G, Li J, et al. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice. Oncotarget. 2015;6:6136-50 pubmed

Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, et al. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells. Int J Oncol. 2015;46:1560-72 pubmed publisher

Kirk J, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, et al. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget. 2015;6:3136-46 pubmed

Molina Molina J, Real M, Jiménez Díaz I, Belhassen H, Hedhili A, Torne P, et al. Assessment of estrogenic and anti-androgenic activities of the mycotoxin zearalenone and its metabolites using in vitro receptor-specific bioassays. Food Chem Toxicol. 2014;74:233-9 pubmed

Libério M, Sadowski M, Soekmadji C, Davis R, Nelson C. Differential effects of tissue culture coating substrates on prostate cancer cell adherence, morphology and behavior. PLoS ONE. 2014;9:e112122 pubmed publisher

Safi R, Nelson E, Chitneni S, Franz K, George D, Zalutsky M, et al. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014;74:5819-31 pubmed publisher

Kokontis J, Lin H, Jiang S, Lin C, Fukuchi J, Hiipakka R, et al. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2. PLoS ONE. 2014;9:e109170 pubmed publisher

Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res. 2014;4:461-73 pubmed

Hessenkemper W, Roediger J, Bartsch S, Houtsmuller A, van Royen M, Petersen I, et al. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells. Mol Endocrinol. 2014;28:1831-40 pubmed publisher

Cui L, Li M, Feng F, Yang Y, Hang X, Cui J, et al. MEIS1 functions as a potential AR negative regulator. Exp Cell Res. 2014;328:58-68 pubmed publisher

Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. PLoS ONE. 2014;9:e103680 pubmed publisher

Li H, Li Y, Morin D, Plymate S, Lye S, Dong X. The androgen receptor mediates antiapoptotic function in myometrial cells. Cell Death Dis. 2014;5:e1338 pubmed publisher

Vander Griend D, Litvinov I, Isaacs J. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. Int J Biol Sci. 2014;10:627-42 pubmed publisher

Tsouko E, Khan A, White M, Han J, Shi Y, Merchant F, et al. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis. 2014;3:e103 pubmed publisher

Al Nakouzi N, Le Moulec S, Albiges L, Wang C, Beuzeboc P, Gross Goupil M, et al. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. Eur Urol. 2015;68:228-35 pubmed publisher

Xie X, Kong Y, Tang H, Yang L, Hsu J, Hung M. Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells. Mol Cancer Ther. 2014;13:1813-25 pubmed publisher

Cai L, Wang D, Fisher A, Wang Z. Identification of a genetic interaction between the tumor suppressor EAF2 and the retinoblastoma protein (Rb) signaling pathway in C. elegans and prostate cancer cells. Biochem Biophys Res Commun. 2014;447:292-8 pubmed publisher

Correa R, Krajewska M, Ware C, Gerlic M, Reed J. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling. Oncotarget. 2014;5:1666-82 pubmed

Erbaykent Tepedelen B, Karamil S, Gonen Korkmaz C, Korkmaz K. DNA damage response (DDR) via NKX3.1 expression in prostate cells. J Steroid Biochem Mol Biol. 2014;141:26-36 pubmed publisher

Ni L, Llewellyn R, Kesler C, Kelley J, Spencer A, Snow C, et al. Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor. Mol Cell Biol. 2013;33:4766-78 pubmed publisher

Hartig S, Feng Q, Ochsner S, Xiao R, McKenna N, McGuire S, et al. Androgen receptor agonism promotes an osteogenic gene program in preadipocytes. Biochem Biophys Res Commun. 2013;434:357-62 pubmed publisher

Teng C, Goodwin B, Shockley K, Xia M, Huang R, Norris J, et al. Bisphenol A affects androgen receptor function via multiple mechanisms. Chem Biol Interact. 2013;203:556-64 pubmed publisher

Hudson R, Yi M, Volfovsky N, Prueitt R, Esposito D, Volinia S, et al. Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. Mol Cancer. 2013;12:13 pubmed publisher

Wang D, Lu J, Tindall D. Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms. Cancer Lett. 2013;335:136-44 pubmed publisher

Eisermann K, Broderick C, Bazarov A, Moazam M, Fraizer G. Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol Cancer. 2013;12:7 pubmed publisher

Shobana R, Samal S, Elankumaran S. Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. J Virol. 2013;87:3792-800 pubmed publisher

Lu Y, Feng F, Yang Y, Gao X, Cui J, Zhang C, et al. LINE-1 ORF-1p functions as a novel androgen receptor co-activator and promotes the growth of human prostatic carcinoma cells. Cell Signal. 2013;25:479-89 pubmed publisher

Liu L, Li Y, Xie N, Shynlova O, Challis J, Slater D, et al. Proliferative action of the androgen receptor in human uterine myometrial cells--a key regulator for myometrium phenotype programming. J Clin Endocrinol Metab. 2013;98:218-27 pubmed publisher

Michel V, Licon Munoz Y, Trujillo K, Bisoffi M, Parra K. Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion. Int J Cancer. 2013;132:E1-10 pubmed publisher

Brayman M, Pepa P, Mellon P. Androgen receptor repression of gonadotropin-releasing hormone gene transcription via enhancer 1. Mol Cell Endocrinol. 2012;363:92-9 pubmed publisher

Zhang Y, Gong M, Yuan H, Park H, Frierson H, Li H. Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation. Cancer Discov. 2012;2:598-607 pubmed publisher

Cherian M, Wilson E, Shapiro D. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. J Biol Chem. 2012;287:23368-80 pubmed publisher

Richards J, Lim A, Hay C, Taylor A, Wingate A, Nowakowska K, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012;72:2176-82 pubmed publisher

Isaacs J, D Antonio J, Chen S, Antony L, Dalrymple S, Ndikuyeze G, et al. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate. 2012;72:1491-505 pubmed publisher

Rivera Gonzalez G, Droop A, Rippon H, Tiemann K, Pellacani D, Georgopoulos L, et al. Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance. Nucleic Acids Res. 2012;40:4825-40 pubmed publisher

Garay J, Karakas B, Abukhdeir A, Cosgrove D, Gustin J, Higgins M, et al. The growth response to androgen receptor signaling in ER?-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res. 2012;14:R27 pubmed

Tsui K, Chang Y, Feng T, Chang P, Juang H. Glycoprotein transmembrane nmb: an androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells. Prostate. 2012;72:1431-42 pubmed publisher

Varisli L, Gonen Korkmaz C, Syed H, Bogurcu N, Debelec Butuner B, Erbaykent Tepedelen B, et al. Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells. Mol Cell Endocrinol. 2012;350:107-17 pubmed publisher

Brayman M, Pepa P, Berdy S, Mellon P. Androgen receptor repression of GnRH gene transcription. Mol Endocrinol. 2012;26:2-13 pubmed publisher

Xie X, Guo J, Kong Y, Xie G, Li L, Lv N, et al. Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy. J Gene Med. 2011;13:680-91 pubmed publisher

Valdez C, Davis J, Odeh H, Layfield T, Cousineau C, Berton T, et al. Repression of androgen receptor transcription through the E2F1/DNMT1 axis. PLoS ONE. 2011;6:e25187 pubmed publisher

Saxena P, Trerotola M, Wang T, Li J, Sayeed A, VanOudenhove J, et al. PSA regulates androgen receptor expression in prostate cancer cells. Prostate. 2012;72:769-76 pubmed publisher

Heer R. Hunterian Lecture. Characterisation of human prostate epithelial progenitor differentiation in response to androgens. Ann R Coll Surg Engl. 2011;93:424-8 pubmed publisher

Marques R, Dits N, Erkens Schulze S, van Ijcken W, Van Weerden W, Jenster G. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS ONE. 2011;6:e23144 pubmed publisher

Chuu C, Kokontis J, Hiipakka R, Fukuchi J, Lin H, Lin C, et al. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc. Cancer Sci. 2011;102:2022-8 pubmed publisher

Shi W, Leong M, Cho E, Farrell J, Chen H, Tian J, et al. Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS ONE. 2009;4:e7398 pubmed publisher